Isolation and characterization of novel human monoclonal antibodies possessing neutralizing ability against rabies virus

Microbiology and Immunology

Volumn 54, Issue 11, 2010, Pages 673-683

  Matsumoto, Takashi ^a   Yamada, Kentaro ^b   Noguchi, Kazuko ^a   Nakajima, Kantou ^c   Takada, Kenzo ^c,d   Khawplod, Pakamatz ^e   Nishizono, Akira ^a,b  

^a OITA UNIVERSITY   (Japan)

^b OITA UNIVERSITY   (Japan)

^c Evec Inc   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

^e THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

Glycoprotein; Human monoclonal antibody; Neutralizing epitope; Rabies virus

Indexed keywords

EPITOPE; GUANINE NUCLEOTIDE BINDING PROTEIN; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY 254; MONOCLONAL ANTIBODY 4D4; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGENIC VARIATION; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG POTENCY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN LOCALIZATION; PROVOCATION TEST; RABIES; RABIES VIRUS; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TRANSFORMATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; HUMANS; MICE; RABIES VIRUS;

ANIMALIA; EQUIDAE; HUMAN HERPESVIRUS 4; RABIES VIRUS;

EID: 78149242978     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2010.00262.x     Document Type: Article

References (50)

1. Rupprecht C.E., Hanlon C.A., Hemachudha T. (2002) Rabies re-examined. Lancet Infect Dis 2: 327-43.
2. Knobel D.L., Cleaveland S., Coleman P.G., Fèvre E.M., Meltzer M.I., Miranda M.E., Shaw A., Zinsstag J., Meslin F.X. (2005) Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 83: 360-8.
3. Meslin F.X., Kaplan M.M., Koprowski H. (1996) Laboratory Techniques in Rabies, 4th edn. Geneva World Health Organization. Chapter in a Book.
4. Smith J.S., Fishbein D.B., Rupprecht C.E., Clark K. (1991) Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med 324: 205-11.
5. WHO. (2005) WHO expert consultation on rabies. World Health Organ Tech Rep Ser 931: 1-88.
6. Manning S.E., Rupprecht C.E., Fishbein D., Hanlon C.A., Lumlertdacha B., Guerra M., Meltzer M.I., Dhankhar P., Vaidya S.A., Jenkins S.R., Sun B., Hull H.F. (2008) Human rabies prevention-United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 57: 1-28.
7. Cabasso V.J. (1976) Rabies immune globulin (human) in the prevention of rabies. Am J Hosp Pharm 33: 48-51.
8. Wilde H., Chomchey P., Punyaratabandhu P., Phanupak P., Chutivongse S. (1989) Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin. Bull World Health Organ 67: 731-6.
9. Rupprecht C.E., Gibbons R.V. (2004) Clinical practice. Prophylaxis against rabies. N Engl J Med 351: 2626-35.
10. Wilde H., Chomchey P., Prakongsri S., Puyaratabandhu P., Chutivongse S. (1989) Adverse effects of equine rabies immune globulin. Vaccine 7: 10-1.
11. Suwansrinon K., Jaijaroensup W., Daviratanasilpa S., Sriaroon C., Wilde H., Sitprija V. (2005) Adverse reactions to human rabies immune globulin manufactured by the Thai Red Cross Society. Vaccine 23: 1324-5.
12. Suwansrinon K., Jaijareonsup W., Wilde H., Benjavongkulchai M., Sriaroon C., Sitprija V. (2007) Sex- and age-related differences in rabies immunoglobulin hypersensitivity. Trans R Soc Trop Med Hyg 101: 206-8.
13. Schumacher C.L., Dietzschold B., Ertl H.C., Niu H.S., Rupprecht C.E., Koprowski H. (1989) Use of mouse anti-rabies monoclonal antibodies in post-exposure treatment of rabies. J Clin Invest 84: 971-5.
14. WHO. (2002) WHO consultation on a rabies monoclonal antibody cocktail for rabies post exposure treatment. WHO, Geneva, 23-24 May 2002, at:
15. Müller T., Dietzschold B., Ertl H., Fooks A.R., Freuling C., Fehlner-Gardiner C., Kliemt J., Meslin F.X., Rupprecht C.E., Tordo N., Wanderler A.I., Kieny M.P. (2009) Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 3: e542.
16. Champion J.M., Kean R.B., Rupprecht C.E., Notkins A.L., Koprowski H., Dietzschold B., Hooper D.C. (2000) The development of monoclonal human rabies virus-neutralizing antibodies as a substitute for pooled human immune globulin in the prophylactic treatment of rabies virus exposure. J Immunol Methods 235: 81-90.
17. Lafon M. (2005) Rabies virus receptors. J Neurovirol 11: 82-7.
18. Prehaud C., Coulon P., LaFay F., Thiers C., Flamand A. (1988) Antigenic site II of the rabies virus glycoprotein: structure and role in viral virulence. J Virol 62: 1-7.
19. Lafon M., Wiktor T.J., Macfarlan R.I. (1983) Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J Gen Virol 64: 843-51.
20. Seif I., Coulon P., Rollin P.E., Flamand A. (1985) Rabies virulence: effect on pathogenicity and sequence characterization of rabies virus mutations affecting antigenic site III of the glycoprotein. J Virol 53: 926-34.
21. Bunschoten H., Gore M., Claassen I.J., Uytdehaag F.G., Dietzschold B., Wunner W.H., Osterhaus A.D. (1989) Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. J Gen Virol 70: 291-8.
22. Benmansour A., Leblois H., Coulon P., Tuffereau C., Gaudin Y., Flamand A., Lafay F. (1991) Antigenicity of rabies virus glycoprotein. J Virol 65: 4198-203.
23. Lafon M., Edelman L., Bouvet J.P., Lafage M., Montchâtre E. (1990) Human monoclonal antibodies specific for the rabies virus glycoprotein and N protein. J Gen Virol 71: 1689-96.
24. Ueki Y., Goldfarb I.S., Harindranath N., Gore M., Koprowski H., Notkins A.L., Casali P. (1990) Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med 171: 19-34.
25. Hanlon C.A., DeMattos C.A., DeMattos C.C., Niezgoda M., Hooper D.C., Koprowski H., Notkins A., Rupprecht C.E. (2001) Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19: 3834-42.
26. Sloan S.E., Hanlon C., Weldon W., Niezgoda M., Blanton J., Self J., Rowley K.J., Mandell R.B., Babcock G.J., Thomas W.D. Jr., Rupprecht C.E., Ambrosino D.M. (2007) Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates. Vaccine 25: 2800-10.
27. Kramer R.A., Marissen W.E., Goudsmit J., Visser T.J., Clijsters-Van der Horst M., Bakker A.Q., De Jong M., Jongeneelen M., Thijsse S., Backus H.H., Rice A.B., Weldon W.C., Rupprecht C.E., Dietzschold B., Bakker A.B., De Kruif J. (2005) The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur J Immunol 35: 2131-45.
28. Prosniak M., Faber M., Hanlon C.A., Rupprecht C.E., Hooper D.C., Dietzschold B. (2003) Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for post-exposure prophylaxis of rabies. J Infect Dis 188: 53-6.
29. Goudsmit J., Marissen W.E., Weldon W.C., Niezgoda M., Hanlon C.A., Rice A.B., Kruif J., Dietzschold B., Bakker A.B., Rupprecht C.E. (2006) Comparison of an anti-rabies human monoclonal antibody combination with human polyclonal anti-rabies immune globulin. J Infect Dis 193: 796-801.
30. De Kruif J., Bakker A.B., Marissen W.E., Kramer R.A., Throsby M., Rupprecht C.E., Goudsmit J. (2007) A human monoclonal antibody cocktail as a novel component of rabies post-exposure prophylaxis. Annu Rev Med 58: 359-68.
31. Bakker A.B., Python C., Kissling C.J., Pandya P., Marissen W.E., Brink M.F., Lagerwerf F., Worst S., Van Corven E., Kostense S., Hartmann K., Weverling G.J., Uytdehaag F., Herzog C., Briggs D.J., Rupprecht C.E., Grimaldi R., Goudsmit J. (2008) First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 26: 5922-7.
32. Dietzschold B., Gore M., Casali P., Ueki Y., Rupprecht C.E., Notkins A.L., Koprowski H. (1990) Biological characterization of human monoclonal antibodies to rabies virus. J Virol 64: 3087-90.
33. Marissen W.E., Kramer R.A., Rice A., Weldon W.C., Niezgoda M., Faber M., Slootstra J.W., Meloen R.H., Clijsters-van der Horst M., Visser T.J., Jongeneelen M., Thijsse S., Throsby M., De Kruif J., Rupprecht C.E., Dietzschold B., Goudsmit J., Bakker A.B. (2005) Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol 79: 4672-8.
34. Bakker A.B., Marissen W.E., Kramer R.A., Rice A.B., Weldon W.C., Niezgoda M., Hanlon C.A., Thijsse S., Backus H.H., De Kruif J., Dietzschold B., Rupprecht C.E., Goudsmit J. (2005) Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 79: 9062-8.
35. Swaminathan S., Huneycutt B.S., Reiss C.S., Kieff E. (1992) Epstein-Barr virus-encoded small RNAs (EBERs) do not modulate interferon effects in infected lymphocytes. J Virol 66: 5133-6.
36. Shiota S., Mannen K., Matsumoto T., Yamada K., Yasui T., Takayama K., Kobayashi Y., Khawplod P., Gotoh K., Ahmed K., Iha H., Nishizono A. (2009) Development and evaluation of a rapid neutralizing antibody test for rabies. J Virol Methods 161: 58-62.
37. WHO. (1992) WHO Expert Committee on Rabies. World Health Organ Tech Rep Ser 824: 1-84.
38. Khawplod P., Wilde H., Benjavongkulchai M., Sriaroon C., Chomchey P. (2007) Immunogenicity study of abbreviated rabies pre-exposure vaccination schedules. J Travel Med 14: 173-6.
39. Ando T., Yamashiro T., Takita-Sonoda Y., Mannen K., Nishizono A. (2005) Construction of human Fab library and isolation of monoclonal Fabs with rabies virus-neutralizing ability. Microbiol Immunol 49: 311-22.
40. Kontermann R.E., Dübel S. (2010) Antibody Engineering, Vol. 1, 2nd edn. Berlin Heidelberg Springer-Verlag. Chapter 20, pp. 307-18.
41. Arakawa M., Yamashiro T., Uechi G., Tadano M., Nishizono A. (2007) Construction of human Fab (gamma1/kappa) library and identification of human monoclonal Fab possessing neutralizing potency against Japanese encephalitis virus. Microbiol Immunol 51: 617-25.
42. Laemmli U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-5.
43. Sumie A., Yamashiro T., Nakashima K., Nasu M., Watanabe M., Nishizono A. (2001) Comparison of genomic structures and antigenic reactivities of orthologous 29-kilodalton outer membrane proteins of Helicobacter pylori. Infect Immun 69: 6846-52.
44. Gras G.S., Dormont D. (1991) Antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus type 1 infection in a human, Epstein-Barr virus-transformed B-lymphocytic cell line. J Virol 65: 541-5.
45. Nakamura M., Sasaki H., Terada M., Ohno T. (1993) Complement-dependent virolysis of HIV-1 with monoclonal antibody NM-01. AIDS Res Hum Retroviruses 9: 619-26.
46. Khawplod P., Shoji Y., Ubol S., Mitmoonpitak C., Wilde H., Nishizono A., Kurane I., Morimoto K. (2006) Genetic analysis of dog rabies viruses circulating in Bangkok. Infect Genet Evol 6: 235-40.
47. Jones D., Kroos N., Anema R., Van Montfort B., Vooys A., Van Der Kraats S., Van Der Helm E., Smits S., Schouten J., Brouwer K., Lagerwerf F., Van Berkel P., Opstelten D.J., Logtenberg T., Bout A. (2003) High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol Prog 19: 163-8.
48. Dietzschold B., Wunner W.H., Wiktor T.J., Lopes A.D., Lafon M., Smith C.L., Koprowski H. (1983) Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc Natl Acad Sci U S A 80: 70-4.
49. Faber M., Faber M.L., Papaneri A., Bette M., Weihe E., Dietzschold B., Schnell M.J. (2005) A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J Virol 79: 14141-8.
50. Takayama-Ito M., Ito N., Yamada K., Sugiyama M., Minamoto N. (2006) Multiple amino acids in the glycoprotein of rabies virus are responsible for pathogenicity in adult mice. Virus Res 115: 169-75.